X-linked Adrenoleukodystrophy Pipeline Summary

DelveInsight’s, “X-linked Adrenoleukodystrophy - Pipeline Insight, 2026” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in X-linked Adrenoleukodystrophy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

X-linked Adrenoleukodystrophy: Understanding

X-linked Adrenoleukodystrophy: Overview

X-linked adrenoleukodystrophy (X-ALD) is a rare, inherited peroxisomal disorder caused by pathogenic variants in the ABCD1 gene. It primarily affects the central and peripheral nervous systems and the adrenal cortex, resulting in a broad spectrum of clinical manifestations, including cerebral adrenoleukodystrophy (CALD), adrenomyeloneuropathy (AMN), and primary adrenal insufficiency. The disease predominantly affects males because of its X-linked inheritance, while female carriers may develop milder neurological symptoms later in life.

X-ALD is caused by pathogenic variants in the ABCD1 gene, which encodes the adrenoleukodystrophy protein (ALDP), a peroxisomal membrane transporter involved in the transport and degradation of very long-chain fatty acids (VLCFAs). The disorder follows an X-linked inheritance pattern, with approximately 95% of affected individuals inheriting the pathogenic variant from a parent, while a small proportion results from de novo mutations.

Deficiency of functional ALDP impairs the peroxisomal ?-oxidation of VLCFAs, leading to their accumulation in plasma and tissues, particularly in the brain, spinal cord, adrenal cortex, and testes. Excess VLCFAs trigger inflammatory demyelination, axonal degeneration, and adrenal cortical dysfunction, resulting in progressive neurological impairment and adrenal insufficiency. The clinical phenotype is highly variable and cannot be predicted by the specific ABCD1 mutation or VLCFA levels alone.

Diagnosis of X-ALD is established through a combination of biochemical and molecular testing. Elevated plasma VLCFA concentrations, particularly hexacosanoic acid (C26:0), and increased C26:0-lysophosphatidylcholine (C26:0-LPC) support the diagnosis, while confirmation is achieved by identifying a pathogenic ABCD1 variant through molecular genetic testing. Brain MRI is essential for detecting cerebral involvement, and newborn screening using C26:0-LPC has been implemented in many regions to enable early diagnosis and timely intervention.

Management of X-ALD depends on the disease phenotype and stage. Early cerebral disease may be treated with hematopoietic stem cell transplantation (HSCT) or ex vivo gene therapy in eligible patients to slow neurological progression. Individuals with adrenal insufficiency require lifelong corticosteroid replacement therapy, while patients with adrenomyeloneuropathy and advanced disease benefit from multidisciplinary supportive care, including physical rehabilitation, symptom management, and regular neurological and endocrine surveillance. Early diagnosis through newborn or family screening is critical to identify patients who may benefit from disease-modifying therapy before irreversible neurological damage occurs.

"X-linked Adrenoleukodystrophy- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the X-linked Adrenoleukodystrophy pipeline landscape is provided which includes the disease overview and X-linked Adrenoleukodystrophy treatment guidelines. The assessment part of the report embraces, in depth X-linked Adrenoleukodystrophy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, X-linked Adrenoleukodystrophy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence X-linked Adrenoleukodystrophy R&D. The therapies under development are focused on novel approaches to treat/improve X-linked Adrenoleukodystrophy.

X-linked Adrenoleukodystrophy Emerging Drugs Chapters

This segment of the X-linked Adrenoleukodystrophy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

X-linked Adrenoleukodystrophy Emerging Drugs

• VK0214: Viking Therapeutics

VK0214 is a novel, orally available, small-molecule thyroid hormone receptor beta (TR?) agonist designed to selectively activate TR?, thereby increasing the expression of the ABCD2 gene, which encodes the adrenoleukodystrophy-related protein (ALDRP), a compensatory peroxisomal transporter. Upregulation of ABCD2 is intended to enhance the metabolism of very long-chain fatty acids (VLCFAs), whose pathological accumulation due to ABCD1 mutations is a hallmark of X-ALD. By reducing plasma and tissue VLCFA levels, VK0214 has the potential to address the underlying disease biology and slow disease progression. The therapy has received Orphan Drug Designation from the U.S. FDA for X-ALD and has demonstrated favorable safety, tolerability, and significant reductions in VLCFA levels in clinical studies. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of X-linked Adrenoleukodystrophy.

Further product details are provided in the report……..

X-linked Adrenoleukodystrophy: Therapeutic Assessment

This segment of the report provides insights about the different X-linked Adrenoleukodystrophy drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in X-linked Adrenoleukodystrophy

There are approx. 3+ key companies which are developing the therapies X-linked Adrenoleukodystrophy. The companies which have their X-linked Adrenoleukodystrophy drug candidates in the most advanced stage, i.e. Phase I include, Viking Therapeutics and others.

• Phases

DelveInsight’s report covers around 3+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

X-linked Adrenoleukodystrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

X-linked Adrenoleukodystrophy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses X-linked Adrenoleukodystrophy therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging X-linked Adrenoleukodystrophy drugs.

X-linked Adrenoleukodystrophy Report Insights

• X-linked Adrenoleukodystrophy Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

X-linked Adrenoleukodystrophy Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing X-linked Adrenoleukodystrophy drugs?
• How many X-linked Adrenoleukodystrophy drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of X-linked Adrenoleukodystrophy?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the X-linked Adrenoleukodystrophy therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for X-linked Adrenoleukodystrophy and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Viking Therapeutics
• Rectify Pharma

Key Products

• VK0214
• Research Program